S18:E3 – Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits

Hematology / Oncology @Point of Care Podcasts
30/11/2023 28 min Temporada 18 Episodio 3
S18:E3 – Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits

Listen "S18:E3 – Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits"

Descargar episodio Ver en sitio original

Episode Synopsis

In this episode our faculty take a look at the ins and outs of molecular testing in patients with HR+ positive breast cancer.
Visit www.morningcommutepodcast.com/HRPositiveBreast3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

More episodes of the podcast Hematology / Oncology @Point of Care Podcasts

S18:E2 – Morning Commute Podcast: Embracing HER2-Low, Trop2-Directed, and Other Newer Approaches to HR-Positive Breast Cancer 30/11/2023
S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer? 29/12/2023
S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer 29/12/2023
S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer 29/12/2023
S20:E1 – Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC) 29/01/2024
S20:E2 – Latest Clinical Trial Data of Emerging, TROP2-Targeting Agents in Advanced NSCLC 29/01/2024
S20:E3 – Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies 29/01/2024
S21:E1 – Improving Survival With HMA Maintenance Therapy in AML 30/09/2024
S21:E2 – Individualizing Care Plans for Patients With AML 30/09/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA